The upcoming 5th edition of the World Health Organization (WHO) Classification of
Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in …

Breast implant-associated anaplastic large cell lymphoma (BIA ALCL) is a newly described
clinicopathologic entity. The purpose of this study is to describe the imaging findings of …

Background Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, and venetoclax, an inhibitor of
B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic …

Purpose Breast implant–associated anaplastic large-cell lymphoma (ALCL) is a recently
described clinicopathologic entity that usually presents as an effusion-associated fibrous …

Transfer of next-generation sequencing technology to a Clinical Laboratory Improvement
Amendments–certified laboratory requires vigorous validation. Herein, we validated a next-…

Increasing use of fine needle aspiration for oncological diagnosis, while minimally invasive,
poses a challenge for molecular testing by traditional sequencing platforms due to high …

The huge parallel sequencing capabilities of next generation sequencing technologies
have made them the tools of choice to characterize genomic aberrations for research and …

Purpose Breast implant–associated anaplastic large-cell lymphoma (BI-ALCL) is a rare type
of T-cell lymphoma that arises around breast implants. The optimal management of this …

Background Ponatinib and blinatumomab are effective therapies in patients with Philadelphia
chromosome-positive (Ph-positive) acute lymphoblastic leukaemia, and their combination …

BACKGROUND Mutations in the tumor protein 53 (TP53) gene predict a poor prognosis in
patients with acute myeloid leukemia (AML). METHODS Peripheral blood or bone marrow …